Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival - PubMed (original) (raw)
Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival
D B Smith et al. Eur J Cancer Clin Oncol. 1987 Jul.
Abstract
The records of 480 patients who received systemic therapy for advanced breast cancer in the University Hospital of South Manchester from 1975 to 1983 were examined. There were 264 with infiltrating duct carcinomas (IDC) and 33 with infiltrating lobular carcinomas (ILC) for whom the response to endocrine therapy was known. There were 92 responses (35%) among the IDC patients and 9 (27%) among the ILC patients. Sixty-seven per cent of IDC patients tested had steroid hormone receptor positive tumours compared to 90% for ILC (P less than 0.001). Comparison of survival from diagnosis, disease free interval and survival from relapse showed no significant differences between the two groups. Thus despite almost all ILC patients having hormone receptor positive tumours their survival was similar to that of IDC patients. This appears to be due to a lower than expected response rate to endocrine therapy. This is a further indication of the different biological characteristics of these two histological sub-types of breast carcinoma.
Similar articles
- Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S, Hui JYC, Huang JL, Kizy S, Beckwith H, Blaes AH, Rueth NM, Tuttle TM. Marmor S, et al. Cancer. 2017 Aug 15;123(16):3015-3021. doi: 10.1002/cncr.30699. Epub 2017 Apr 5. Cancer. 2017. PMID: 28382636 - Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ. van de Water W, et al. Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3. Eur J Cancer. 2013. PMID: 22954666 Clinical Trial. - Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, Omata M, Oyama T. Inoue M, et al. Breast Cancer. 2017 Sep;24(5):667-672. doi: 10.1007/s12282-017-0753-4. Epub 2017 Jan 20. Breast Cancer. 2017. PMID: 28108967 - Infiltrating lobular carcinoma of the breast: systemic treatment.
Farese SA, Aebi S. Farese SA, et al. Breast Dis. 2008-2009;30:45-52. doi: 10.3233/BD-2009-0281. Breast Dis. 2008. PMID: 19850995 Review. - Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast.
Jacobs C, Clemons M, Addison C, Robertson S, Arnaout A. Jacobs C, et al. Breast J. 2016 Jan-Feb;22(1):45-53. doi: 10.1111/tbj.12520. Breast J. 2016. PMID: 26782951 Review.
Cited by
- Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Jirström K, Rydén L, Anagnostaki L, Nordenskjöld B, Stål O, Thorstenson S, Chebil G, Jönsson PE, Fernö M, Landberg G. Jirström K, et al. J Clin Pathol. 2005 Nov;58(11):1135-42. doi: 10.1136/jcp.2005.027185. J Clin Pathol. 2005. PMID: 16254100 Free PMC article. Clinical Trial. - The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
Fiorillo M, Sanchez-Alvarez R, Sotgia F, Lisanti MP. Fiorillo M, et al. Aging (Albany NY). 2018 Dec 20;10(12):4000-4023. doi: 10.18632/aging.101690. Aging (Albany NY). 2018. PMID: 30573703 Free PMC article. - ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R. Riggins RB, et al. Cancer Res. 2008 Nov 1;68(21):8908-17. doi: 10.1158/0008-5472.CAN-08-2669. Cancer Res. 2008. PMID: 18974135 Free PMC article. - Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.
Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M. Domagala W, et al. Virchows Arch A Pathol Anat Histopathol. 1993;423(6):497-502. doi: 10.1007/BF01606541. Virchows Arch A Pathol Anat Histopathol. 1993. PMID: 8291222 - Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G, Bardou VJ, Clark GM, Elledge RM. Arpino G, et al. Breast Cancer Res. 2004;6(3):R149-56. doi: 10.1186/bcr767. Epub 2004 Feb 17. Breast Cancer Res. 2004. PMID: 15084238 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical